RadNet (NASDAQ:RDNT) Stock Gets Price Target Boost from KeyCorp

RadNet (NASDAQ:RDNT) had its price target upped by stock analysts at KeyCorp from $92.00 to $95.00 in a report released on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. KeyCorp‘s price objective would suggest a potential upside of 21.20% from the company’s current price.

RDNT has been the topic of a number of other research reports. Jefferies Financial Group reiterated a “buy” rating on shares of RadNet in a report on Friday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a research note on Wednesday, November 4th. Truist Financial raised their price objective on RadNet from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Barclays lifted their price objective on RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 28th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of RadNet in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $90.43.

RadNet Stock Performance

NASDAQ:RDNT opened at $78.38 on Tuesday. The company has a market cap of $6.17 billion, a P/E ratio of -290.29 and a beta of 1.42. The firm’s 50 day moving average is $72.64 and its two-hundred day moving average is $65.43. RadNet has a fifty-two week low of $50.82 and a fifty-two week high of $85.84. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.94.

RadNet (NASDAQ:RDNT) last announced its quarterly earnings data on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.08. The company had revenue of $638.26 million during the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.20 EPS. Analysts expect that RadNet will post 0.49 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of RadNet in the second quarter valued at about $675,768,000. JB Capital Partners LP acquired a new position in RadNet during the 2nd quarter worth approximately $87,821,842. Dimensional Fund Advisors LP lifted its position in RadNet by 1.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,379,003 shares of the medical research company’s stock worth $77,074,000 after acquiring an additional 19,188 shares in the last quarter. Bamco Inc. NY purchased a new position in RadNet in the 2nd quarter worth approximately $77,765,000. Finally, Van Berkom & Associates Inc. boosted its holdings in RadNet by 24.9% in the 1st quarter. Van Berkom & Associates Inc. now owns 1,028,586 shares of the medical research company’s stock worth $57,488,000 after acquiring an additional 204,858 shares during the period. Institutional investors and hedge funds own 77.90% of the company’s stock.

RadNet News Summary

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: Adjusted EPS of $0.30 beat the $0.22 consensus by about 35%. Revenue rose 22.1% year over year to $638.3 million, and the company reported record quarterly revenue and adjusted EBITDA. RadNet Q3 results and updated guidance
• Positive Sentiment: RadNet raised its FY 2026 outlook for the third consecutive quarter, with revenue guidance of $2.5 billion–$2.6 billion, versus a consensus estimate around $2.5 billion. Higher guidance signals continued confidence in growth. RadNet Q3 earnings and raised guidance
• Positive Sentiment: An analyst highlighted the ONRAD acquisition as a potential value and growth driver: it expands RadNet’s inpatient presence and geographic reach, and ONRAD’s reported EBITDA margins above 30% could make the deal margin-accretive. Advanced imaging growth, operating leverage and AI-related cost controls were also cited as supporting profitability. Analyst view on RadNet’s earnings and acquisition
• Negative Sentiment: Quarterly revenue of $638.3 million came in slightly below analysts’ $640.0 million estimate, tempering an otherwise strong report. RadNet quarterly earnings report

RadNet Company Profile

RadNet, Inc operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging.

The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.

RadNet also develops digital health and artificial intelligence solutions through its subsidiary DeepHealth, including technology intended to support imaging workflows and assist with image analysis.